283 related articles for article (PubMed ID: 27699623)
1. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
Clements JN; Threatt T; Ward E; Shealy KM
Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.
Clements JN; Bello L
Am J Health Syst Pharm; 2016 Mar; 73(6):359-66. PubMed ID: 26953280
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
5. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
6. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
7. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
Goldman J; White JR
Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
[TBL] [Abstract][Full Text] [Related]
8. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
9. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
Hurren KM; O'Neill JL
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
[TBL] [Abstract][Full Text] [Related]
11. The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.
Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Horiuchi R; Utsunomiya K
Diabetes Technol Ther; 2017 Aug; 19(8):457-462. PubMed ID: 28605286
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
[TBL] [Abstract][Full Text] [Related]
14. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
15.
Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
[No Abstract] [Full Text] [Related]
16. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN; Syed YY
BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
[TBL] [Abstract][Full Text] [Related]
17. Optimizing glycemic control with insulin glargine.
Williams JB
Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
[No Abstract] [Full Text] [Related]
18. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
Vargas-Uricoechea H
J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
[TBL] [Abstract][Full Text] [Related]
19. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
20. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]